LSPN Europe: understand our business models, say in-house lawyers
26-11-2019
LSPN Europe: AIs should be named inventors, argues Dabus professor
21-11-2019
LSPN Europe: English contract law still ‘fit for purpose’ despite Brexit
21-11-2019
Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
LSPN 19, Hogan Lovells, Natalia Gulyaeva, Novartis, MA, market authorisation, compulsory licensing
